Press Release

Stent Market to Grow with a CAGR of 6.46% through 2028

Surge in prevalence of heart diseases and increase in demand for angioplasty is expected to drive the Global Stent Market growth in the forecast period, 2024-2028.


According to TechSci Research report, “Stent Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Stent Market stood at USD 10.06 billion in 2022 and is anticipated to grow with a CAGR of 6.46% in the forecast period, 2024-2028. The increasing prevalence of chronic cardiovascular diseases across the globe is one of the key factors that is driving the growth of the market. With the rising burden of heart-related conditions such as coronary artery disease and heart failure, there is a growing demand for effective treatment options and diagnostic tools.

Additionally, the increasing geriatric population, who are more susceptible to cardiovascular diseases, has also played a significant role in contributing to the growth of the market. As the elderly population continues to expand, the need for innovative therapies and interventions to manage and prevent cardiovascular diseases becomes even more crucial. The market is witnessing a surge in research and development efforts to address these challenges and improve patient outcomes.



Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Stent Market.”



The growth of the global stents market is primarily driven by factors such as the increasing prevalence of coronary artery disease, advancements in stent technology, funding from private and government organizations for healthcare sector development and research centers, and the rising demand for drug eluting stents. According to the Centers for Disease Control and Prevention (CDC), approximately 360,900 population died due to coronary artery disease in 2019, making it one of the most common types of heart disease. For example, in August 2021, Sinomed, a leading international medical device company, announced the European launch of HT Supreme Drug eluting stent at the University Hospital Galway.


Moreover, the rise in drug approvals is expected to further fuel the growth of the stent market. In October 2020, the U.S. Food and Drug Administration (FDA) approved the Venous Self-Expanding Stent system for the treatment of iliofemoral venous outflow obstruction. Additionally, in June 2021, Abbott announced the FDA approval for Abbott XIENCE stent, specifically for high bleeding risk patients.


Furthermore, the increase in the geriatric population and the prevalence of chronic diseases contribute to the growth of the stents market, as older individuals are more susceptible to cardiovascular disease. According to the Journal of Jama Cardiology, in 2019, approximately 38.0% of the population died due to heart failure, with the majority being above the age of 65 years. The Centers for Disease Control and Prevention (CDC) reported in September 2021 that around 18.2 million individuals aged 20 years and older are diagnosed with coronary artery disease.


In September 2020, the U.S. Food and Drug Administration (FDA) approved the Treo Abdominal stent graft system for the treatment of patients diagnosed with abdominal aortic aneurysms. Unhealthy diet habits and lack of physical activity are also contributing to the rise in cardiovascular diseases. Technological advancements in medical infrastructure and the availability of percutaneous coronary intervention (PCI) procedures further propel the market's growth.


The global stents industry has witnessed significant growth in recent years. The increasing prevalence of cardiovascular diseases (CVDs) worldwide is a key driver for market growth. According to the World Health Organization, CVDs are the leading cause of death globally, claiming an estimated 17.9 million lives each year. Stents have become a crucial device in the treatment of obstructive coronary disease for patients with high-risk cardiovascular conditions such as heart attack or stroke. Additionally, the growing number of cardiovascular surgeries performed using minimally invasive techniques contributes to the market's expansion.


Furthermore, the development of innovative and groundbreaking stent technologies presents various opportunities in the market. However, stringent government regulations for stent approval and market launch, along with the high cost of stents, pose challenges to market growth.


The Global Stent Market is segmented into product type, biomaterial, end user, regional distribution, and company.


Based on product type, the Drug-eluting Stents Segment is anticipated to experience growth during the forecast period. A drug-eluting stent is a peripheral or coronary stent that is inserted into clogged, diseased peripheral or coronary arteries. It gradually releases a drug to inhibit cell proliferation. Due to the rise in the incidence of cardiac disorders, there is a growing global demand for coronary stents. According to the CDC, in 2020, approximately 20.1 million adults aged 20 and older in the United States had coronary heart disease (CAD), making it the most prevalent type of heart disease in the country. The high prevalence of cardiac diseases among the population has fueled the demand for stents.


The growth of the segment is driven by technological advancements, increasing product approvals, and key players' partnerships and acquisitions. For example, in January 2022, Cook Medical received a breakthrough device designation from the US FDA for a new drug-eluting stent designed for below the knee (BTK) use. This innovative stent is used to treat individuals with limb-threatening persistent ischemia. In August 2021, Sinomed launched its HT Supreme drug-eluting stent in Ireland. Such product launches are expected to contribute to the segment's growth throughout the forecast period.



Based on region, North America segment is expected to grow during the forecast period. North America is anticipated to dominate the stents market during the forecast period due to several factors. These include the increasing prevalence of chronic diseases, the growing geriatric population, the strong presence of industry players in the region, improved healthcare infrastructure, and heightened awareness among people and healthcare industry stakeholders regarding available technologies in the area.


Furthermore, the rise in the geriatric population and the incidence of lifestyle diseases significantly impact the market's growth. For instance, the 2021 census by Statistics Canada revealed that there were approximately 7,021,430 individuals aged 65 years or older, with 3,224,680 being males and 3,796,750 being females. This age group is particularly susceptible to critical cardiovascular diseases that necessitate stent-based treatments. Consequently, the increasing geriatric population in the region is expected to bolster market growth.


Moreover, the active involvement of key market players and institutions in research and development activities aimed at innovating stents for various conditions is projected to further drive market expansion. For example, in October 2021, Boston Scientific Corporation presented positive clinical trial results for the Eluvia drug-eluting vascular stent system during the Vascular InterVentional Advances (VIVA) meeting in Las Vegas. The findings from the EMINENT trial showcased the superior performance of the Eluvia stent compared to self-expanding bare metal stents (BMS) in treating patients with peripheral arterial disease (PAD) and superficial femoral artery (SFA) lesions up to 210 mm in length. This study, involving 775 patients, stands as one of the largest randomized trials for drug-eluting stents in peripheral artery disease treatment. Such clinical trials are expected to drive the adoption of stents in the region. 


Major companies operating in Global Stent Market are:

  • Medtronic plc
  • B. Braun Melsungen AG
  • Terumo Corporation
  • MicroPort Scientific Corporation
  • Meril Life Sciences Pvt. Ltd
  • Translumina GmbH
  • Biosensors International Group Limited
  • Boston Scientific Corporation


Download Free Sample Report

Customers can also request for 10% free customization on this report.


“The global stents market is experiencing significant growth, primarily driven by a surge in the prevalence of heart diseases and the increasing demand for angioplasty procedures. Additionally, the rise in the number of approvals for stents further contributes to the market expansion. However, it is worth noting that the high cost associated with these procedures poses a hindrance to the overall market growth. Nevertheless, the market is poised to witness new opportunities in the coming years. This can be attributed to the continuous increase in research and development activities in the field of stent technology. With advancements in technology, innovative solutions are expected to emerge, presenting potential avenues for market growth and improved patient outcomes.” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.


Stent Market Segmented By Product Type (Drug-Eluting Stent, Bare Metal Coronary Stent, and Bioabsorbable Stent), By Biomaterial (Metallic Biomaterial, Polymeric Biomaterial, and Natural Biomaterial), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Region and Competition, Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global Stent Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Stent Market.



Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email:[email protected]


Relevant News